Recursion Pharmaceuticals: AI-driven drug pipeline, Sanofi/Roche milestones, and cash runway to 2028.

Recursion Pharmaceuticals aims to address multiple points of failure in drug development by combining AI-driven biology, chemistry, and clinical execution. The company has consolidated its portfolio to five clinical programs and 15 discovery programs, and achieved initial milestones on five programs with Sanofi. Partnerships, including with Roche, will support the business model.